

January 21, 2025  
IPGaia, Inc.  
University of Miami

**IPGaia and the University of Miami Announce  
Agreement to Evaluate Potential Drug Candidates**

IPGaia Inc. (President & CEO, Yasunori Yamaguchi, "IPG") and the University of Miami have entered into an agreement where University of Miami presents potential drug candidates for development with IPG.

This Agreement enables the University of Miami to propose drug targets to IPG for identification and development of lead compounds or modalities with the goal of licensing clinical development candidates to pharmaceutical companies. IPG is soliciting drug discovery seeds from a wide range of research institutions, including global academia and pharmaceutical companies. IPG continues to expand steadily both domestically and internationally, with the University of Miami joining as the eleventh academic institution (Five institutions in Japan, five institutions in the United States, and one in Singapore). Through the efficient development of ground-breaking medicine, IPG is committed to addressing global challenges by reducing healthcare costs and improving access to essential medicines.

Upon the conclusion of this agreement, Norma Kenyon, PhD, Vice Provost for Innovation at University of Miami said, "We are thrilled to have another avenue for our researchers to further develop their innovations. IPG allows University of Miami researchers to bring cutting-edge technology closer to the market"

"We are greatly honored and privileged to establish this agreement with the University of Miami, one of the top research universities in US," said Yasu Yamaguchi, Ph.D., President and CEO of IPG. "This partnership enables IPG to utilize cutting-edge drug discovery seeds, allowing us to develop advanced innovative medicines more efficiently. IPG is committed to actively addressing global challenges such as rising healthcare costs and extending healthy life expectancy."

### **About IPG**

IPG was established on October 26, 2021, as a wholly owned subsidiary of the Healthcare New Platform Fund where Whiz Partners Inc. (Headquarters: Minato-ku, Tokyo; President and CEO: Tomoyuki Fujisawa) has been the general partner. IPG selects promising research seeds and projects to build a next stage drug discovery platform by generating high quality innovative pharmaceuticals in a shorter period of time and lower cost. As for the pharmaceutical industry, the trend of the horizontal division of labor business model would be more accelerating. IPG plays a role as a platformer for creating pre-clinical stage innovative new medicines.

### **About the University of Miami**

The University of Miami is one of America's top research universities located in one of the most dynamic and multicultural cities in the world. With more than \$456 million in research and sponsored program expenditures annually, the University of Miami is a member of the prestigious Association of American Universities (AAU). Only 3 percent of four-year institutions in the nation are invited to join the AAU, which recognizes breadth and quality of research and scholarship. While the majority of this work is housed at the Miller School of Medicine, investigators conduct hundreds of studies in other areas, including marine science, engineering, education, and psychology.